Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies
Human cytomegalovirus (HCMV) is an important pathogen in transplant patients and in congenital infection. Previously, we demonstrated that vaccination with a recombinant viral glycoprotein B (gB)/MF59 adjuvant formulation before solid organ transplant reduced viral load parameters post transplant. R...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
PNAS
2018
|
| Subjects: |